Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Accured Expenses (2016 - 2025)

KalVista Pharmaceuticals' Change in Accured Expenses history spans 10 years, with the latest figure at $8.1 million for Q2 2025.

  • For Q2 2025, Change in Accured Expenses rose 433.26% year-over-year to $8.1 million; the TTM value through Apr 2025 reached $8.9 million, up 178.62%, while the annual FY2025 figure was $14.4 million, 349.64% up from the prior year.
  • Change in Accured Expenses for Q2 2025 was $8.1 million at KalVista Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.1 million in Q2 2025 and bottomed at -$2.4 million in Q2 2024.
  • The 3-year median for Change in Accured Expenses is $2.9 million (2024), against an average of $2.1 million.
  • The largest annual shift saw Change in Accured Expenses tumbled 43.23% in 2024 before it skyrocketed 433.26% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at $4.0 million in 2023, then rose by 25.49% to $5.0 million in 2024, then soared by 61.11% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Change in Accured Expenses are $8.1 million (Q2 2025), $5.0 million (Q4 2024), and -$1.8 million (Q3 2024).